Adaptimmune drops after ending partnership with GSK

Adaptimmune Therapeutics

25/10/2022 15:22

** Shares of cancer therapies developer Adaptimmune
Therapeutics  ADAP.O  fall 5.9% to $1.13 after co ends
partnership with GSK to develop cancer therapies  GSK.L  
    **  GSK will transfer its NY-ESO cell therapy program and
the right to the PRAME cell therapy program to Adaptimmune
 urn:newsml:reuters.com:*:nNFCgx3kD
    ** Pending agreement on the transfer of the NY-ESO cell
therapy program to Adaptimmune, GSK will continue to be
responsible for the execution and costs of ongoing clinical
trials. 
    ** Termination of agreement does not trigger any payment
obligations on the part of Adaptimmune
    ** More than 280,000 shares change hands, nearly half of the
stock's 25-day moving average volume
    ** YTD stock down 69.7%
 (Reporting by Nandhini Srinivasan in Bengaluru)
 ((nandhini.srinivasan@thomsonreuters.com))